AJR Am J Roentgenol

1. PERRY H
   Artificial Intelligence May Be a Useful Tool to Predict the Likelihood of Ipsilateral Breast Cancer Recurrence in Patients Treated for DCIS.
   AJR Am J Roentgenol. 2026 Mar 4. doi: 10.2214/AJR.26.34787.
   

   >> Share

   
   
2. LAM DL, Rahbar H
   Strengthening the Case for Personalized Breast Cancer Screening Approaches.
   AJR Am J Roentgenol. 2026 Mar 4. doi: 10.2214/AJR.26.34789.
   

   >> Share

   
   

   
   Ann Oncol

3. CURIGLIANO G, Hu X, Dent R, Yonemori K, et al
   Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.
   Ann Oncol. 2026 Mar 2:S0923-7534(26)00071-2. doi: 10.1016/j.annonc.2026.
   

   >> Share

   
   

   
   Ann Surg Oncol

4. KLIMBERG VS
   ASO Author Reflections: Intracavitary Radiofrequency Ablation as a Means to Deescalate Radiation in Patients with Breast Cancer.
   Ann Surg Oncol. 2026 Mar 4. doi: 10.1245/s10434-026-19437.
   

   >> Share

   
   

   
   Anticancer Res

5. JOHANSSON G, Kyriakogiannaki A
   Plan Quality Variability in Radiotherapy of Whole Breast and Regional Lymph Nodes: An Intra-institutional Analysis.
   Anticancer Res. 2026;46:1557-1568.
   

   >> Share

   
   

   
   BMC Cancer

6. FENG L, Liang Y, Huang J, Xu S, et al
   Evaluation of organs at risk (OARs) in whole-breast irradiation: a comparison of prone, supine position and with deep inspiration breath-hold techniques-subgroup analysis from a prospective study.
   BMC Cancer. 2026;26:307.
   

   >> Share

   
   
7. GUTIERREZ-GONZALEZ A, Maciel-Cruz EJ, Reynoso-Noveron N, Mohar-Betancourt A, et al
   Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis.
   BMC Cancer. 2026 Mar 4. doi: 10.1186/s12885-026-15808.
   

   >> Share

   
   

   
   Br J Cancer

8. JIANG H, Livingston M, Room R, Kibret AA, et al
   Alcohol consumption and mortality from four alcohol-related cancers in Australia 1950-2018: a time series analysis.
   Br J Cancer. 2026;134:914-923.
   

   >> Share

   
   

   
   Breast Cancer Res

9. ZOU L, Tang X, Deng P, Liu Y, et al
   Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study.
   Breast Cancer Res. 2026 Mar 4. doi: 10.1186/s13058-026-02254.
   

   >> Share

   
   

   
   Breast Cancer Res Treat

10. TOLOSA P, Garcia-Fructuoso I, Pascual T, Martinez-Saez O, et al
    Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.
    Breast Cancer Res Treat. 2026;216:21.
    

    >> Share

    
    

    
    Breast J

11. LI J, Zhang J
    OGT-Mediated O-GlcNAcylation Stabilizes c-Myc Activity and Promotes Chemoresistance in Triple-Negative Breast Cancer.
    Breast J. 2026;2026:2120017.
    

    >> Share

    
    

    
    Eur Radiol

12. VAN DER WAAL D, Abbey CK, Tetteroo E, Geertse TD, et al
    Finding the optimal recall rate in breast cancer screening: results from the ROCS study.
    Eur Radiol. 2026 Mar 5. doi: 10.1007/s00330-026-12370.
    

    >> Share

    
    

    
    J Biol Chem

13. DOLUI B, Majumdar B, Bandyopadhyay A, Desai KV, et al
    TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response.
    J Biol Chem. 2026;302:111096.
    

    >> Share

    
    

    
    J Clin Invest

14. ZHU XZ, Zhou YF, Ying XH, Wang YY, et al
    Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance.
    J Clin Invest. 2026;136:e188989.
    

    >> Share

    
    

    
    J Clin Oncol

15. LI T, Zhou T, Wang B, Tao Z, et al
    Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).
    J Clin Oncol. 2026 Mar 4:JCO2502021. doi: 10.1200/JCO-25-02021.
    

    >> Share

    
    

    
    J Natl Cancer Inst

16. SAMPATHKUMAR Y, Zakaria Z, O'Connell K, Bhimani J, et al
    Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.
    J Natl Cancer Inst. 2026 Mar 4:djag063. doi: 10.1093.
    

    >> Share

    
    

    
    Nature

17. SAFONOV A, Lee M, Brown DN, Boscolo Bielo L, et al
    Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.
    Nature. 2026 Mar 4. doi: 10.1038/s41586-026-10197.
    

    >> Share

    
    

    
    NPJ Breast Cancer

18. MARRA A, Kim SH, Pareja F, Basili T, et al
    Tracking response to neoadjuvant systemic therapy through circulating tumor DNA analysis in breast cancer.
    NPJ Breast Cancer. 2026 Mar 5. doi: 10.1038/s41523-026-00921.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

19. COTTRELL O, Rowntree A, Chopra K, Mackellar E, et al
    HES1 oscillations are required for cell cycle reentry in oestrogen receptor-positive breast cancer cells.
    Proc Natl Acad Sci U S A. 2026;123:e2520724123.
    

    >> Share

    
    
20. SENTHILKUMAR I, Vangheel J, Kumar V, McNamara L, et al
    Stress-dependent growth in breast cancer arises from a mechano-osmotic coupling and cell-sizing checkpoint.
    Proc Natl Acad Sci U S A. 2026;123:e2523159123.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share